menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

CSL prepares to slash R&D as it grapples with looming Trump tariffs

17 1
13.07.2025
The market is focused on a mooted 200 per cent levy on the pharmaceutical giant’s goods. There are far more significant changes afoot at the company.

© Financial Review